{"entity":{"id":"nct06478719","kind":"trial","name":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","aka":[],"tldr":"A phase 1/2 trial of Placebo in hepatocellular carcinoma, run by Febico Biomedical Corp., now recruiting.","summary":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization is a phase 1/2 interventional study registered as NCT06478719 by Febico Biomedical Corp., with 120 participants planned, started 2024-06-24 and due to reach its primary completion in 2028-06-07. Interventions recorded: Placebo and FB-1603.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06478719","url":"https://clinicaltrials.gov/study/NCT06478719"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06478719","phase":"1/2","setting":"A Phase I/II Randomized, Double-blinded Study of FB-1603 to Evaluate the Safety and Efficacy in Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization (FECHT Trial)","sponsor":"Febico Biomedical Corp.","enrolled":120,"outcomes":[]},"route":"/trials/nct06478719/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}